Calamos Advisors’s Jackson Acquisition Company Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 RJAC.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-375,000
Closed -$3.43K 1322
2022
Q4
$3.43K Buy
+375,000
New +$16.1K ﹤0.01% 1170

Other funds holding RJAC.WS

Calamos Advisors's RJAC.WS Position: Q1 2023 in Review

Calamos Advisors sold out of Jackson Acquisition Company Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 (RJAC.WS) in Q1 2023, closing a stake of 375,000 shares — an estimated $3.43K sold.

Calamos Advisors first reported a position in RJAC.WS in Q4 2022 and held it in 1 quarter. The position peaked at $3.43K in Q4 2022. 8 funds tracked by Wall St. Rank hold RJAC.WS as of Q1 2023.

  • Calamos Advisors reported no remaining Jackson Acquisition Company Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 position as of Q1 2023 after selling out during the quarter.
  • Calamos Advisors sold 375,000 Jackson Acquisition Company Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 shares in Q1 2023, an estimated $3.43K.
  • Calamos Advisors first reported a position in Jackson Acquisition Company Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 in Q4 2022 and held it in 1 quarter.
  • Calamos Advisors's Jackson Acquisition Company Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 position peaked at $3.43K in Q4 2022.
  • 8 funds tracked by Wall St. Rank held Jackson Acquisition Company Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 as of Q1 2023.

Based on Calamos Advisors's 13F filing for Q1 2023, filed 4 May 2023.